|Kindred Biosciences, Inc.|
1555 Bayshore Highway
United States - Map
Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The companys product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidate is SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs, cats, and horses. The company's other small molecule product candidates consist of KIND-010 for management of weight loss in cats; and KIND-012 for treatment of fevers in horses. It is also developing biologics products, such as KIND-510, a feline erythropoeitin for treatment of anemia in cats; KIND-502 for the treatment of allergic and immune-mediated diseases; KIND-506 for the treatment of inflammatory and autoimmune diseases; KIND-507 for the treatment of immune-mediated diseases; KIND-504, a cancer vaccine; and KIND-501, an antiangiogenic biologic for cancer in dogs. The company was founded in 2012 and is headquartered in Burlingame, California.
|Kindred Biosciences, Inc.’s ISS Governance QuickScore as of May 1, 2015 is 7. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 9; Compensation: 3.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Richard Chin M.D.,
Co-Founder, Chief Exec. Officer, Pres and Director
|Ms. Denise M. Bevers ,
Co-Founder, Chief Operating Officer and Sec.
|Dr. Stephen Sundlof D.V.M., PH.D.,
Chief Scientific Officer and Exec. VP of Regulatory Affairs & Quality
|Dr. Noe Reyes D.V.M,
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|